Showing results (1961-1970 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 9, 2021
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumorsNoboru Yamamoto, Toshio Shimizu, Kan Yonemori, et al.
Investigational New Drugs|February 17, 2021
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignanciesSarina A Piha-Paul, Kyaw Z Thein, Paul De Souza, et al.
Investigational New Drugs|February 17, 2017
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)Susanne M Arnold, Kari Chansky, Markos Leggas, et al.
Investigational New Drugs|March 12, 2017
Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agentsKamil Piska, Paulina Koczurkiewicz, Adam Bucki, et al.
Investigational New Drugs|March 17, 2017
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II studyRavi Salgia, R Waide Weaver, Michael McCleod, et al.
Investigational New Drugs|March 18, 2017
A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancerM Thomas, P Sadjadian, J Kollmeier, et al.
Investigational New Drugs|January 1, 1987
Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)G J Peters, S L Sharma, E Laurensse, et al.
Investigational New Drugs|February 4, 2017
Association of an aurora kinase a (AURKA) gene polymorphism with progression-free survival in patients with advanced urothelial carcinoma treated with the selective aurora kinase a inhibitor alisertibAndrea Necchi, Giulia Pintarelli, Daniele Raggi, et al.
Investigational New Drugs|February 6, 2017
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumorsPatricia M LoRusso, Mrinal Gounder, Shadia I Jalal, et al.
Investigational New Drugs|August 8, 2019
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumorsMark N Stein, Susan Goodin, Murugeson Gounder, et al.
Pageof 372